Drug Profile

CB 011

Alternative Names: CB-011

Latest Information Update: 28 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Caribou Biosciences
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Beta 2-microglobulin expression modulators; Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Multiple myeloma
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I Multiple myeloma

Most Recent Events

31 Dec 2023 CB 011 receives Orphan Drug status for Multiple myeloma (Second-line therapy or greater) in USA, before December 2023
03 May 2023 Caribou Biosciences has patent protection for CB 011 in USA
04 Apr 2023 CB 011 receives Fast Track designation for Multiple myeloma [Parenteral] (Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com